Vaccination and Immunization

A clinician-reported misinformation tracker at Children's Hospital of Philadelphia found vaccines accounted for 53.8% of 234 entries and informed education on 28 topics.

This FAQ breaks down the AAP's newest COVID-19, RSV, and influenza recommendations for clinicians who want a quick refresher on what changed for the 2026-2027 season.

Five rapid developments — new mRNA flu vaccine, CDC director, ACIP/NVAC charters, a vaccine order, and an HHS RFI — roil the 2026 schedule.

Court fight over CDC 2026 childhood vaccine schedule shifts shots to shared decision-making; experts warn lower uptake for Hep A, B, flu, COVID.

CDC's 2025 NIS-Teen data show HPV vaccine coverage flat for a fourth year, with rural adolescents 12 points behind urban peers in receiving ≥1 dose.

The AAP's 2026-2027 policy recommends universal vaccination for infants 6-23 months and a risk-based single dose for children 2-18 years.

Independent review of hundreds of studies finds flu vaccine 80% effective against pediatric death; RSV and maternal immunization cut infant hospitalizations.

AAP guidance expands RSV immunization eligibility for children aged 8 through 19 months at high risk of severe disease.

Navigate back-to-school vaccine requirements, evidence, and FAQs—plus the latest measles data and new pneumococcal options for pediatric practice.

Executive order seeks to trim routine childhood vaccines, split combination shots, and push parent-doctor decisions—sparking debate as measles surges.

A 173-mother cohort study found parenting role models—not income alone—drove the link between maternal education and COVID-19 vaccination intent.

US measles cases have climbed to 2,318 in 2026, already exceeding all of 2025 and marking the country's highest annual total since 1991, as CDC data show falling MMR coverage continuing to fuel outbreaks.

A 2-million-infant Swedish registry study found intramuscular vitamin K nonreceipt rose over 19 years and nearly tripled the odds of intracranial bleeding by 6 months.

A 10-year King County study found MMRV was the first vaccine for 15% of children who were disproportionately Hispanic, Black, or VFC eligible.

A study found that nonmedical childhood vaccine exemptions have increased significantly across US counties since 2010.